TENAX THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
TENX$1.69-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| The year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses | ||
| General and administrative | $5,005,135 | $5,675,231 |
| Research and development | 3,228,806 | 5,377,412 |
| Total operating expenses | 8,233,941 | 11,052,643 |
| Net operating loss | 8,233,941 | 11,052,643 |
| Interest expense | 23,967 | 4,443 |
| Other income, net | (547,235) | (9,191) |
| Net loss | $7,710,673 | $11,047,895 |
| Total comprehensive loss | $7,710,673 | $11,047,895 |
| Net loss per share, basic and diluted | $(31.04) | $(600.71) |
| Weighted average number of common shares outstanding, basic and diluted | 248,447 | 18,391 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.